Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts

Virtual. 2–5 December 2020
Published: 24 March 2021

Oral Communications

1. Cytokines and immune cell populations performance during nivolumab treatment. A subgroup analysis of NIVACTOR study
Andrea Abbona1,*, M. Paccagnella1, Nerina Denaro2, A. Falletta1, Danilo Galizia3, Lorena De Zarlo3, Erika Fiorino5, Loretta Gammaitoni4, Dario Sangiolo5, Marco Carlo Merlano1
1Dipartimento di Oncologia, Azienda Ospedaliera St Croce e Carle, Cuneo, Italy; 2Medical Oncology, Azienda Ospedaliera St Croce e Carle, Cuneo, Italy; 3Medical Oncology, IRCCS Candiolo Institute, Turin, Italy; 4Medical Oncology, FPO-IRCCS Candiolo Institute, Turin, Italy; 5Department of Oncology, University of Turin, Turin, Italy
Correspondence: Andrea Abbona - abbona.andrea@gmail.com
Journal of Translational Medicine 2020; 19(Supp 1): 1

Background: Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (R-M SCCHN) is a major clinical issue with a year survival rate of 20–30% and a median overall survival (OS) of 10 months [1, 2]. Nivolumab, anti-PD1 mAb, is approved for 2nd line R-M HNC, but only 15–20% of patients will benefit [3]. Therefore, there is an unmet need for robust predictive markers for patient selection.

Patients and methods: We analyzed changes of plasma circulating cytokines and immune cells during treatment at baseline (T0), at day 1 cycle 3 (T1), at day 1 cycle 7 (T2) and at disease progression (TPD). Cytokines’ concentrations were assessed using Simple Plexsystem (ProteinSimple). Immune cells from peripheral blood were analyzed by flow cytometry using FACS Cyan (Cyan ADP, Beckman Coulter) and analyzed with Summit Software. Principal component analysis (PCA) was performed to group patients with good or poor progression free survival (PFS) and OS using cut-off based on regression points of their extracted factors: group B (patients with factor 1 < 0.7 and factor 2 < 0.0) and remaining patients in group A.

Results: 18 patients were analyzed for both cytokine and immune cell populations. CCL-4 increased from T0 to T2 (P = 0.047) [Fig. 1]. Using PCA analysis we clustered patients in group B and group A on their T0 levels of IL-5, IL-6, CD3+CD8+LAG3+, CD3+CD8+PD1+LAG3+ and CD8+TEMRA [Fig. 2]. Then we performed Cox analysis using cut-off from regression points of their factors extracted with PCA observing a significant better PFS and OS in patients of group B (HR 0.185, P = 0.030 and HR 0.063, P = 0.010 respectively) [Fig. 3]. We also found that patients with increased levels of Treg cells from T0 to T1 had better PFS (HR 0.098, P = 0.001) [Fig. 4]. Longitudinal analysis showed that TNF-α and IFN-γ increased from T0 to TPD (P = 0.049 and P = 0.035, respectively).

Fig. 1 (Abstract 1) Distributions of 17 plasma cytokine levels during nivolumab treatment. Cytokines concentration was expressed in pg/mL. Data are shown as median with range

Fig. 2 (Abstract 1) PCA analysis using T0 values of IL-5, IL-6, CD3+CD8+LAG3+, CD3+CD8+PD1+LAG3+ and CD8+TEMRA as parameters. Group B includes patients (n = 5) with factor 1 < 0.7 and factor 2 < 0; group A includes the other patients (n = 13)
Conclusions: Our results show that nivolumab could increase the levels of CCL-4 from T0 to T2. TNF-α and IFN-γ increased at TPD. Moreover, the increasing of Treg percentages during treatment could be biomarker for poor prognosis.

Acknowledgements
This study is presented on behalf of NIVACTOR study group.

References
1. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008; 371:1695–709.
2. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papilloma virus related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26:662–9.
3. Robert L, Ferris, George Blumenstein, Jerome Fayette et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck N Engl J Med 2016; 375:1856–1867.

2. Sequential therapy in stage IV melanoma – real-world SECOMBIT
Teresa Amaral1,2*, Olivia Seber1, Stephanie Sanchez2, Ulrike Keim1, Ioannis Thomas1, Andreas Michael1, Andrea Forschner1, Thomas Eigentler1, Claus Garbe1
1Centre for Dermatooendocrinology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany; 2Portuguese Air Force Health Care Direction, Lisbon, Portugal
Correspondence: Teresa Amaral - Teresa.Amaral@med.uni-tuebingen.de
Journal of Translational Medicine 2020, 19(Suppl 1): 2.

Background: The approval of immune checkpoint inhibitors (ICI) and targeted therapies (TT) have changed the outcome of stage IV melanoma. Yet, data from clinical trials on the best therapy sequence are missing, particularly in patients with BRAFV600 mutated melanoma.

Material and methods: Here we analyzed pts diagnosed with stage IV melanoma between January 2015 and December 2018 in the Center for Dermato-Oncology of the Tuebingen University, and treated with ICI (PD1, CTLA4) or TT (BRAF) or combinations of both. Moreover, Cox analyses for PFS and OS of group A (blue line, n = 13) and group B (green line, n = 5) derived from PCA analysis (Abstract 1) were performed. We found that the sequence ICI-TT was associated with a higher OS when pts progress under 1st line therapy. There was no significant difference in terms of OS between the four sequences.

Conclusions: Second-line therapies seem to have a modest impact in OS when pts progress under 1st line therapy. There was no significant difference in terms of OS between the four sequences.

3. Neoadjuvant nivolumab in early stage colon cancer induces promising tumor regression and T cell infiltration
Antonio Asallone1*, A. De Stefano1, U. Pace1, A. Catteau1, E. Di Gennaro1, F. Tatangelo2, I. Boquet3, A. Cassatta1, S. Costantini4, S. De Franciscis5, F. Collina3, N. Zanaletti3, C. Vitagliano1, V. Granata1, D. Giannarelli1, S. Lastoria6, Paolo Antonio Ascierto7, Jerome Galon8, P. Delrio9, Alfredo Budillon9*
1Experimental Clinical Abdominal Oncology, Istituto Nazionale Tumori Fondazione G. Pascale IRCCS, Napoli, Italy; 2Colorateral Surgery, Istituto Nazionale Tumori Fondazione G. Pascale IRCCS, Napoli, Italy; 3HalioDx, Luminy Biotech Enterprise, Marseille Cedex, France; 4Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale IRCCS, Napoli, Italy; 5Pathology, Istituto Nazionale Tumori Fondazione G. Pascale IRCCS, Napoli, Italy; 6Radiology, Istituto Nazionale Tumori Fondazione G. Pascale IRCCS, Napoli, Italy; 7Unit di Biostatistica, IFO-Istituto Nazionale per lo Studio e la Cura dei Tumori Regina Elena – Roma, Italy; 8Nuclear Medicine, Istituto Nazionale Tumori Fondazione G. Pascale IRCCS, Napoli, Italy; 9Cancer Immunotherapy and Development Therapeutics, Istituto
Background: Neoadjuvant treatment is well established in early stage solid tumors but few trials have been conducted in colon cancer. In mismatch repair deficient (dMMR) colon cancer patients programmed death 1 (PD-1) blockade is highly effective in metastatic setting and plus cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade induced high pathological response rate in early stages.

Material and Methods: NICOLE is the first neoadjuvant study to test anti PD-1 nivolumab in unselected MMR early stage resectable colon cancer (T3-T4) patients (NCT04123925). Primary endpoints were safety, feasibility, pathological tumor response, molecular and immunophenotypic studies. 22 patients (19 pMMR and/or MSS, 3 dMMR and/or MSI) received nivolumab at 240 mg flat dosage on day 1 + 15, and underwent surgery within 3 weeks thereafter without delay or complications.

Results: Major pathological responses (<20% viable tumor cells) were observed in 3 pMMR/MSS, including 1 complete response, and in 1 pMMR/MSI tumors. In additional 4 confirmed MSS tumors we observed >30% tumor regression. A clear downsloping was observed in more than 70% of pts. Double blind pathological evaluation is ongoing. At surgery tumors from NICOLE cohort showed significantly higher level of CD8 T-cells infiltration (p = < 0.035) and significant higher Immunoscore (densities of CD3+ and CD8+ T-cells in tumor and invasive margin regions) (p = 0.028), compared to a control cohort of 22 colon cancer patients undergoing surgery without treatment. Moreover, a significant increase in tumor CD8 T-cells infiltration was seen at surgery compared to pre-treatment biopsy (p = < 0.0015) in the NICOLE cohort. On the contrary no significant differences were observed between baseline and preoperative radiological and metabolic assessment. Analysis of blood biomarkers (cytokines, metabolomics, immune cell subpopulations, tumor immune gene signature and microbiota profiling) are ongoing.

Conclusions: Overall, neoadjuvant nivolumab in early stage colon cancer patients is feasible, do not compromise surgery and leads to an increase of tumor T-lymphocytes infiltration. The promising tumor regression observed in pMMR/MSS patients, suggest a potential of preoperative combination treatment with immunotherapy in this setting.

4. Safety and Efficacy of TRIplet combination of Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in Patients (pts) with BRAF-mutated Metastatic Melanoma (MM): a Single Center Phase II Study

Elizabeth M. Burton1, Rodabe N. Amaria1, Isabella Claudia Gitzaz1, Adi Diab1, Denai R. Milton2, Sapna Praduman Patel2, Jennifer McQuade3, Virginia Honaker4, Elizabeth M. Burton - emburton@mdanderson.org

Journal of Translational Medicine 2020; 19(Suppl 1): 4.

Background: Although targeted therapies (TT) and immunotherapies (IMT) have improved survival for pts with BRAF V600 mutated stage IV MM, many pts progress and will ultimately die from their disease. Preclinical data has shown that BRAF inhibition (BRAFi) in BRAF-mutated tumors is associated with increased T cell infiltration, supporting the rationale for a clinical combinatorial approach with IMT. Although trials evaluating triplet combinations in the IMT naïve setting have reported mixed results, with one triplet gaining FDA approval, there are no approved therapies for pts after IMT failure. Notably, pts with untreated brain metastases (BM) are also excluded from such trials. We hypothesized that N in combination with DT is safe and will demonstrate clinical activity in BRAF-mutated pts naïve or refractory to PD1 therapy and in pts with BM.

Methods: We report a single arm phase II study (NCT02910700) of NDT in pts with BRAF-mutated, unresectable stage III or stage IV MM. Prior IMT was allowed, but pts who received prior BRAF/MEKi were ineligible. Pts with untreated BM and asymptomatic or mildly symptomatic/requiring stable or decreasing steroids (up to PO dexamethasone of 8 mg or equivalent) were also allowed. Pts received 3 mg/kg Q2wks of N (later amended to 480 mg q4wks), 150 mg BID of D and 2 mg QD of T, all starting on Day 1. The primary objective is to determine safety and efficacy (ORR by RECIST 1.1) of the NDT combination. We performed continuous monitoring for safety and futility using Bayesian stopping rules. Longitudinal tissue and blood samples were collected to assess for future correlative analyses.

Results: Following a 6 pt safety run-in with no observed DLTs, 27 pts received NDT—17 pts were PD1 refractory. 10 were PD-1 naïve. 10 of these 27 pts had a history or presence of BM. Median follow up was 18.4mos (3.2–45.9), ORR for 26 evaluable pts was 92%, including 3 pts who achieved a CR. 16 PD1 refractory pts were evaluable for response; 2 achieved CR and 12 PR (ORR 88%). Each of the 10 evaluable PD-1 naïve pts achieved a response. 4 of the 7 evaluable pts with a BM achieved an intracranial response (57%), including 2 CRs. The median PFS for all pts was 8.5 months – (8.5mos in PD1 naïve pts and 8.2mos in PD1 refractory pts), the median OS was not reached. Median PFS for pts without BM was 8.5mos and 8mos for those with BM. 78% of pts experienced treatment related grade 3/4 AEs and only 6 pts discontinued due to toxicities.

Conclusions: NDT at full doses of all 3 agents has a toxicity profile consistent with previously reported triplet combinations and shows promising clinical activity in pts with IMT refractory disease and with BM. There were no significant differences in outcomes between pts with and without BM. Further translational investigation to better delineate mechanisms of response are ongoing.

5. Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

Adi Diab1, Scott S. Tykodi2, Gregory A. Daniels1, Michele Maio1, Brendan D. Curti3, Karl D. Lewis5, Sekwon Jang6, Ewa Kalinka7, Igor Puzanov1, Alexander I. Spira8, Daniel C. Cho1, Shanhong Guan1, Erika Puente1, Ute Hoch1, Sue L. Currie1, Tuan Nguyen7, Wei Lin1, Mary A. Tagliabue1, Jonathan Zalevsky4, Mario Sznol1, Michael E. Hurwit8, Antonio Avallone9, Abi Diab - adiab@mdanderson.org

Journal of Translational Medicine 2020; 19(Suppl 1): 5.

Background: An unmet need exists for novel therapies that produce deep and durable responses in more patients with metastatic melanoma (metMEL). Encouraging clinical activity was observed with the CD122-preferential IL-2 pathway agonist bempedalgesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metMEL in the phase 1/2 PIVOT-02 trial (NCT02983045)[1], leading to FDA Breakthrough Therapy designation. We present updated clinical results from PIVOT-02 (NCT02983045) in first-line metMEL, and biomarkers of response.

Methods: 41 patients with previously untreated stage IV melanoma (known PD-L1 status by immunohistochemistry; 28–8 PharmDx) received ≥1 dose of BEMPEG (0.006 mg/kg) plus NIVO (360 mg)
q3wks; 38 patients were efficacy-evaluable (≥ 1 post-baseline tumor scan). Primary endpoints were safety and objective response rate (ORR; RECIST v1.1; BICR); other endpoints included PFS, OS and biomarkers. Polynuclear strength index (PSI) of circulating lymphocytes (determined using single-cell cytokine analysis [Isoplexis]) and eosinophil count (determined from hematologic analysis) at baseline and Cycle 1-Day 8 were analyzed using the median cut-off for correlations with ORR and PFS. Biomarkers, including CDB+ tumor infiltrating lymphocytes (TIL) and interferon-gamma (IFNg) gene expression profile (GEP), were measured in baseline tumor biopsies and analyzed for correlation with ORR and PFS.

Results: At median follow-up of 29.0 months (1-Sept-2020), ORR by BICR was 53% (20/38 patients). Complete response occurred in 13/38 patients (34%): 23% PD-L1-negative (< 1% tumor cell expression); 41% PD-L1-positive (≥ 1% tumor cell expression). Further deepening of response was observed, with 18/38 patients (47%) achieving 100% reduction in target lesions and a 79% median reduction from baseline in tumor size (previously 62% [11]). Median time to response and time to complete response was 2.0 and 7.9 months, respectively. Median PFS was 30.9 months (95% CI: 5.3; NE; ITT). Median OS was not reached; 2-year OS rate was 77% (95% CI: 60–87; ITT). Safety was consistent with previous reports [1]. IFNg GEP and CDB+ TIL in baseline tumor biopsies were significantly associated with ORR and PFS. Analysis of Cycle 1-Day 8 blood samples demonstrated significant increases in CD4+ PSI, CD8+ PSI, and eosinophils from baseline. Increased CD8+ PSI was significantly associated with higher ORR and PFS; increased eosinophils were significantly associated with higher ORR.

Conclusions: BEMPEG plus NIVO was well tolerated in first-line metast-MEL. Responses were deep and durable, with a complete response rate of 34% and a median PFS of 30.9 months. Non-invasive, on-treatment biomarkers predicted response, well before radiologic evidence. A phase 3 trial evaluating BEMPEG plus NIVO in first-line metastMEL is enrolling (NCT03635983).

Acknowledgements
This study was supported by Nektar Therapeutics.

Trial registration
NCT2983045

Reference
1. Dabbagh A, Puzanov I, Maio M, et al. Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study. Oral presentation at STC; November 6-10, 2019; National Harbor, MD, USA. Abstract #035.

6. Pretreatment neutrophil–lymphocyte ratio (NLR) predicted overall survival (OS) for metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) patients who received monotherapy with immune checkpoint inhibitor as ipilimumab, nivolumab or pembrolizumab

Pietro Di Marino*, Francesca Chiara Primavera, Maria Teresa Martino, Consiglia Carella, Antonino Grassadonia, Clara Natoli, Michele De Tursi.

1Clinical Oncology Unit, S. S. Annunziata Hospital, 66,100 Chieti, Italy; 2Department of Medical, Oral and Biotechnological Sciences and Center for Advance Studies and Technology (CAST), G. D’Annunzio University, 66,100 Chieti, Italy

Correspondence: Pietro Di Marino - pietrodmarino@gmail.com

Journal of Translational Medicine 2020, 19(Suppl 1): 6

Background: Melanoma is one of the most immunogenic tumors and immunotherapy treatment with checkpoint inhibitors (ICI), such as anti-programmed cell death protein (PD)-1 antibodies, has significantly improved the prognosis of metastatic melanoma. However, only half of the patients responds to this therapy and has a favorable outcome [1]. Understanding the factors responsible for treatment failure and early identification of responders are both important to select the best therapeutic strategy for each patient. Thus, the aim of our study was to investigate clinical biomarkers of response to treatment with anti-PD-1 antibodies.

Materials and methods: We identified all patients with inoperable stage III or stage IV melanoma (N = 147), subjected to first-line treatment with anti-PD-1 at IDI-IRCCS in the last 10 years. We studied the associations between patients’ different clinical features and progression-free survival (PFS), using the Cox proportional hazard models.

Results: In the multivariate analysis, an increased risk of disease progression was observed among patients with stage M1d, who developed brain metastases (with HR 2.92; 95% CI 1.38–618), compared to patients with stage M1a-M1b with skin, subcutaneous, soft tissue, lymph node and/or lung lesions. Moreover, the risk of progression was greater in patients with the Eastern Cooperative Oncology Group Performance Status (ECOG PS) 1 (HR:2.67; 95% CI: 1.30–5.52), and in patients with ECOG PS ≥ 2 (HR:2.21; 95%CI:1.06–4.63) with respect to PS 0 ECOG 0. High levels of lactate dehydrogenase (LDH) at baseline was
associated with a major risk of disease progression (HR 2.09; 95% CI: 1.16–3.75) (Table 1). In a sub-group analysis (48 patients), we evaluated neutrophil count, the neutrophil/lymphocyte ratio (NLR) and the derived (d)NLR before the beginning of anti-PD-1 therapy and we observed that these values were higher among disease progression patients, with respect to those who responded to therapy.

**Table 1 (Abstract 7) Clinical biomarkers of response to anti-PD-1 and progression free survival. This Table 1 belongs to Abstract 7**

| Univariate | Multivariate* |
|------------|---------------|
| **Types of Melanoma (cutaneous, mucosal, uveal)** | **Types of Melanoma (cutaneous, mucosal, uveal)** |
| Crude HR (95%CI) | Adjusted HR (95%CI) |
| ECOG performance status |  |  |  |  |
| 0 | 1 | 1 | 1 | 1 |
| 1 | 2.13 (1.09–4.16) | 0.026 | 2.67 (1.30–5.52) | 0.008 |
| ≥ 2 | 3.08 (1.56–6.05) | 0.001 | 2.21 (1.06–4.63) | 0.035 |
| Stages of metastasis |  |  |  |  |
| 1a-1b | 1 | 1 | 1 | 1 |
| 1c | 1.88 (1.04–3.48) | 0.036 | 1.80 (0.95–3.41) | 0.074 |
| 1d | 3.18 (1.66–6.08) | <0.0001 | 2.92 (1.38–6.18) | 0.005 |
| LDH serum |  |  |  |  |
| Normal | 1 | 1 | 1 | 1 |
| High | 2.32 (1.34–4.01) | 0.003 | 2.09 (1.16–3.75) | 0.014 |

**Conclusions:** In our study population, the main independent predictors of diseases progression among patients treated with anti PD-1 first-line were as following: ECOG PS, staging and LDH. Further studies are warranted to confirm our findings.

**Ethics Approval:**
For this study, approval was obtained from the Ethics Committee of the IDI-IRCCS (Opinion Register No. S10/5 and subsequent amendments).

**Reference**
1. Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017; 6:2,106,132–10,614

**9. Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: an in vitro study**
Luigi Fattore1,2, Giusy Gentilecore1,2, Gianluca Sbardella1, Gerardo Botti1, Rita Mancini1, Paolo A. Ascierto2 and Gennaro Ciliberto3
1SAFU Laboratory, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy; 2Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy; 3Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, Fisciano, SA, Italy; 4Department of Molecular and Clinical Medicine, University of Roma “Sapienza”, Rome, Italy; 5IRCCS, Istituto Nazionale Tumori “Regina Elena”, Scientific Directorate, Rome, Italy

**Correspondence:** Luigi Fattore - luigifattore1985@gmail.com
Journal of Translational Medicine 2020; 19(Suppl 1): 9.

**Background:** BRAF + MEK inhibitors have become the standard of care for melanoma patients (approximately 50%) harboring BRAF-V600 mutations. However, drug resistance often impairs the efficacy of this combinatorial approach. Hence, the need to identify additional therapeutic approaches capable to control the development of drug resistance and to avoid disease relapse. Towards this goal, our group has been largely involved in the last years in the study of non-mutational mechanisms involved in the acquisition of drug resistance. For example, we reported that monoclonal antibodies targeting ErbB3 receptor are able to delay the emergence of resistance to target therapy in vitro and in vivo. More recently, we have also demonstrated that microRNAs are key players of resistance to target therapy in melanoma and that their targeting is able to restore drug sensitivity. Here, we have started to investigate whether reverse transcriptase inhibitors (RTIs) frequently used in the treatment of AIDS can act in combination with target therapy to fight the development of drug resistance.

**Material and methods:** Human melanoma cell lines, namely M14 and A375 harboring BRAF-V600E mutation have been treated with different concentration of either BRAFI and/or MEKI in the presence or not of the non-nucleoside RTI, i.e. SPV122. MTI and colony formation assays have been used to determine cell proliferation. Annexin V assay for apoptosis, cell cycle and mitochondrial membrane depolarization have been tested through FACS analyses. DNA double-strand breaks have been determined through Western Blot and Immunofluorescence analyses.

**Results:** Our present work has reported for the first time the capability of RTIs to mitigate drug resistance to target therapy in BRAF-mutant melanomas in vitro. We show that the novel non-nucleoside RTI, SPV122 synergizes with BRAF and MEK inhibitors to: 1) impair BRAF-mutant melanoma cell growth; 2) induce apoptosis; 3) block cell cycle progression and 4) delay the emergence of resistance in vitro. Mechanistically, we also show that this combination provokes DNA double-strand breaks, mitochondrial membrane depolarization and increased ROS levels.

**Conclusions:** Our in vitro results pave the way for the combinatorial use of RTI + BRAFI + MEKI as a novel therapeutic option for BRAF-mutant melanoma patients and warrant further investigation in vivo models.
using modified protein-binding single-stranded DNA aptamers called SOMAmers, revealed on a high dimension oligo-probe array. The raw hybridization data were normalized using hybridization controls and were log2-transformed. Transformed HybNormalized BM and PB plasma data were compared using GraphPad PRISM 8. Multiple comparisons were set with an FDR threshold of 0.01%. **Results:** The comparative analysis between plasma samples from BM and PB showed that 228 proteins are differentially expressed in BM and PB plasma irrespective of the nature of disease (Table 1). A more detailed mix-effect analysis of protein expression in the different patient categories and compartment defined in Table 1 revealed that out of these 228 proteins, 92 showed a significant differential expression when performing a mixed-effect analysis between the different groups. Among the top 20 proteins differentially expressed between BM and PB, 18 show differential expression between patient groups. The patient group effect is dominated by the differences between BM and PB plasma in ALL Common patients, which account for 17 of the observed differences in protein levels. In spite of the limited sample size, the analysis revealed a difference in NOTC2 level between ALL Common PB and ALL Pro-B PB.

**Conclusion:** In our study we applied a quantitative large-scale proteomic analysis on BM and PB plasma in children suffering from ALL, identifying differential protein expression between the two compartments.

In the last few years, SomaScan has emerged as a very attractive method due to its high throughput capacity, faster discovery mode compared to other proteomic platforms and small sample size required, which make it ideal for the identification of novel biomarkers. In fact, differences in protein expression were revealed in these limiting samples sizes. We are taking this analysis further by analyzing more patients in different groups and including normal donor samples.

**Table 1 (Abstract 9).**

| Pts Code | Age (yrs) | Phenotype | Cytogenetics | Bone Marrow | Peripheral Blood |
|----------|-----------|-----------|--------------|-------------|-----------------|
| ALL#02P  | 1.5       | B-cell ALL common | Normal | Yes |
| ALL#03P  | 1.5       | B-cell ALL common | Complex karyotype | Yes |
| ALL#05P  | 15        | B-cell ALL common | Normal | Yes |
| ALL#09P  |           | T-cell ALL | Normal | Yes |
| ALL#10P  | 8         | B-cell ALL common | Normal | Yes |
| ALL#11P  | 12        | B-cell ALL common | Normal | Yes |
| ALL#12P  | 5         | Pro-B ALL | Normal | Yes |
| ALL#13P  | 11        | B-cell ALL common | t(1;19) | Yes |
| ALL#14P  | 12        | Pro-B ALL | Normal | Yes |
| ALL#15P  | 7         | T-cell ALL | Normal | Yes |
| ALL#16P  | 16        | B-cell ALL common | Normal | Yes |
| ALL#17P  | 15        | T-cell ALL | Normal | Yes |
| ALL#18P  | 1.5       | B-cell ALL Common | Normal | Yes |
| ALL#18P  | 3         | B-cell ALL Common | t(12;21) | Yes |
| ALL#20P  | 5         | B-cell ALL Common | t(12;21) | Yes |
| ALL#21P  | 14        | ALL B Mature | t(8;14) | Yes |

10. **Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches**

Burçak Ş. Karaca¹, Ahmet Sezer², Sezgin S. Göksu², İrfan Çiçin⁴, Dilek Erdem³, Erdem Cübbükçu³, Faysal Dano³, İlhan Hacıbekiroğlu⁵, Berna Okuşzioğlu⁶, Ebru Alnıgeniş¹⁰, İsmail Gelik¹¹

¹Ege University Hospital, Department of Internal Medicine, Division of Medical Oncology, İzmir, Turkey; ²Başkent University Adana Dr. Turgut Noyan Practice and Research Centre, Department of Medical Oncology, Adana, Turkey; ³Akdeniz University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Antalya, Turkey; ⁴Trakya University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Edirne, Turkey; ⁵Bahçeşehir University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Istanbul, Turkey; ⁶Uludağ University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Bursa, Turkey; ⁷Marmara University Istanbul Pendik Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, İstanbul, Turkey; ⁸Sakarya University Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, Sakarya, Turkey; ⁹Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Medical Oncology Clinic, Ankara, Turkey; ¹⁰Novartis Oncology, Istanbul, Turkey; ¹¹Hacettepe University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Ankara, Turkey

**Correspondence:** Burçak Ş. Karaca - karacakurbacak@hotmail.com

**Journal of Translational Medicine** 2020, 19(Supp 1): 10.

**Background:** Turkey has some limits in reaching some new treatment options. Our aim was to determine the current diagnostic and treatment approaches of metastatic cutaneous melanoma (MCM) in ten main oncology clinics in Turkey. To the best of our knowledge, this is the first epidemiological registry study specific for MCM status in Turkey.

**Materials and methods:** This was a cross-sectional, retrospective epidemiological registry study. Data was collected from patients’ file records. Patients with MCM diagnosis between December 2017 and June 2019 were eligible.

**Results:** Totally 140 patients were eligible for the registry; 62.9% of them were male. Median age at the diagnosis was 56 years. Primary tumour localization was predominantly lower extremity (32.4%). The most common histological subtype was nodular melanoma (57.8%). Of the patients, 90.3% were classified with the Eastern Cooperative Oncology Group as 0 or performance status of 1. Primary tumour was found in 75% of the patients. From all cases, quarter of them had progressed from being stage III disease and 14% of them from being stage II at the time of diagnosis. The median Breslow thickness was 5 mm and ulceration was present in 37% of the patients. Sentinel lymph node dissection was not performed in about 80% of all cases. Of the patients, 31.9% had M1c disease 14.3% had brain metastasis at the time of MCM diagnosis. BRAF mutation status was mainly analysed by real-time polymerase chain reaction and was positive in 39.3% of the patients. Radiotherapy was applied mostly for palliative reasons (75%) and mostly for brain metastases. The most common first line treatment was temozolomide in 67% of all patients and this was followed by ipilimumab (33%) as a second line treatment. Nivolumab was only applied in 9.6% of the patients in the first line treatment and in 24.7% of the patients in the second line of treatment. Among BRAF inhibitors, dabrafenib and trametinib combination was the most preferred one; nearly 25% of the patients received this combination as a first line treatment.

**Conclusions:** Chemotherapy is preferred in the front line for BRAF wild type patients, which leads to worsened outcomes. Dabrafenib and trametinib combination is preferred for most of the BRAF mutant patients, but some patients could not receive any BRAF inhibitors. This study highlighted that there is still unmet need for early diagnosis of melanoma and the importance of access to effective treatment options for all melanoma patients.

11. **Circulating levels of miR-204-5p predict response to BRAF and MEK inhibitors in metastatic melanoma patients**

Ciro F. Ruggerio¹, Irene Terrenato², Luigi Fattore², Valentina Salvati², Francesca Sperati³, Domenico Liguoro⁴, Vittorio Castaldo⁴, Gabriele Madonna⁵, Marialena Capone⁶, Antonio Grimaldi⁶, Diana Giannarelli⁶, Paolo A. Ascierto⁷, Rita Mancini⁷ and Gennaro Ciliberto⁸

¹Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Catanzaro, Italy; ²IRCCS, Regina Elena National Cancer Institute, Rome, Italy; ³San Gallicano Dermatological Institute, Rome, Italy; ⁴Cancer Institute, Rome, Italy; ⁵San Gallicano Dermatological Institute, Rome, Italy; ⁶Department of Medical Oncology, University “Magna Graecia” of Catanzaro, Catanzaro, Italy; ⁷RCCS, Regina Elena National Cancer Institute, Rome, Italy; ⁸San Gallicano Dermatological Institute, Rome, Italy.
Background: Metastatic melanomas harboring BRAF-V600 mutations are currently treated with combinations of BRAF and MEK inhibitors (MAPKi) increasing the objective responses, disease free survival and overall survival over monotherapy with BRAF inhibitors. Unfortunately, several patients suffer from ab initio or acquired resistance to these agents. Several efforts have been directed in recent years to understand mechanisms of resistance to MAPKi inhibitors. These studies have shown a prominent involvement of non-mutational adaptive events, among which also deregulation of miRNAs expression. In this regard our laboratory has identified several miRNAs which undergo either up- or down-regulation during the development of drug resistance [1]. In this study we have started to assess whether circulating levels of one or more of these miRNAs can act as an early predictor of response to therapy.

Materials and methods: Circulating miRNAs were extracted from the serum of 51 BRAF-mutated melanoma patients before the beginning of therapy through miRNAeasy Mini Kit (Qiagen). Real-time PCR for miR-204-5p, miR-199b-5p, miR-579-3p, miR-9-5p, miR-4443 and miR-4488 was assayed by TaqMan Gene Expression. Data of circulating miRNAs were normalized using Global mean normalization and NormFinder model [2]. For analysis purposes, ∆Ct miRNA values were dichotomized on the basis of the cut-off established using the receiver operating characteristics (ROC) curve considering OS specific condition (alive/dead within 12 months from MAPKi therapy) as the state variable. Overall Survival (OS) and Progression Free Survival (PFS) analyses were carried out by the Kaplan–Meier product-limit method. The Log Rank test was used to prove if any statistically significant difference between subgroups exists (p-value < 0.05).

Results: This retrospective study involved patients with a median age of 45 years. Among them, 27 (53%) were females. All patients were treated with MAPKi therapy in first line. Only miR-204-5p emerged to have a role in predicting both OS and PFS. Concerning OS, patients with a ∆Ct value under the ROC cut-off have a shorter median time to death in comparison to patients with a ∆Ct value over the ROC cut-off (10 months 95% confidence interval (95%CI): (3.9–16.1) vs 34 months 95%CI: (25.7–42.3); p-value = 0.013). Concerning PFS analysis, patients with a ∆Ct value under the ROC cut-off have a shorter median time to progression in comparison to patients with a ∆Ct value over the ROC cut-off (5 months 95%CI: (4.1–5.9) vs 18 months 95%CI: (7.9–28.1); p-value = 0.006).

Conclusions: On the basis of these results, miR-204-5p can be a promising predictive biomarker able to discriminate advanced melanoma patients who may benefit of MAPKi treatments. These data warrants of further validation in an extended cohort of patients as well as in prospective following studies.

Bibliography
1. Fattore L, et al. Cell Death Differ. 2019. https://doi.org/10.1038/s41418-018-0205-5.
2. Fogli S, et al. Tumour Biol. 2017; https://doi.org/10.1177/1010428317701646.

12. Characterization of DNA cargo of exosomes derived from irradiated breast cancer cells
Sheila Spada 4*, Paul Zumbo 3, Doron Betel 1, Nils-Petter Rudqvist 1, Tuo Zhang 1, Sandra Demaria 1

1 Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA; 2 Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA; 3 Genomics Resources Core Facility, Weill Cornell Medicine, New York, NY, USA

Correspondence: Sheila Spada - ssh2066@med.cornell.edu
Journal of Translational Medicine 2020, 19(Suppl 1): 12.

Background: Immunogenic dose (8 Gy X 3) of radiation determines an increase of cytosolic DNA that is sensed by cGAS leading to downstream activation of interferon type I (IFN-I) signaling in breast cancer cells. [1–3]. Our previous report demonstrated that irradiated TSA breast cancer cells release tumor-derived exosomes (RT-TEX) containing a DNA cargo that stimulates IFN-I production in recipient dendritic cells (DCs) via the cGAS/STING pathway, whereas exosomes secreted by untreated cells (UT-TEX) contain DNA that is unable to stimulate IFN-I [4]. Furthermore, RT-TEX, but not UT-TEX, when used to vaccinate mice stimulated anti-tumor immune response preventing tumor growth [4]. Here, we hypothesized that the differential capability of RT-TEX and UT-TEX to activate IFN-I in recipient DCs depends on qualitative differences in the DNA cargo of RT-TEX versus UT-TEX.

Materials and methods: Agilent Bioanalyzer system was used to measure the length of DNA purified from TEX and from the cytosolic fraction of TSA cells. Whole-genome sequencing (WGS) and whole-genome bisulfite sequencing were performed to analyze the DNA cargo of TEX. 5-methyl cytosine DNA Elisa kit was used to quantify the percentage of methylation of total DNA in TSA cells.

Results: Enrichment of DNA fragments with size between 60 and 250 bp was found in RT-TEX compared to UT-TEX, as well as in the cytosolic fraction of irradiated compared to mock-treated TSA cells. WGS revealed that TEX DNA cargo represents the entire genome, regardless of RT. More than 99% of TEX DNA was of nuclear origin, but mitochondrial DNA was increased in RT-TEX. Interestingly, we found that RT decreases the level of methylation in both exosomal and total DNA in TSA cells compared to the controls.

Conclusions: Our findings support the hypothesis that immunogenic RT dose alters the molecular characteristics of the exosomal DNA cargo, resembling molecular changes occurring in irradiated TEX-producing breast cancer cells. The enrichment in DNA fragments with size of 60–250 bp in RT-TEX is interesting considering that cGAS is fully activated by DNA in this length range [5]. We are currently investigating which features of the cargo DNA that differ between UT-TEX and RT-TEX may explain the differential ability to induce IFN-I pathway activation in recipient DCs. The identification of a DNA signature associated with the ability of TEX to activate the cGAS pathway could provide a circulating biomarker of the RT-driven immunogenic tumor response.

References
1. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraj Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15,618.
2. Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548(7668):461–5.
3. Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548(7668):466–70.
4. Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, et al. Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunol Res. 2018;6(8):910–20.
5. Du M, Chen ZJ. DNA-induced liquid phase condensation of cGAS activates innate immune signaling. Science. 2018;361(6403):704–9.
13. The clonal heterogeneity of circulating tumor cells (CTCs) drives their metastatic potential: a new NOD-SCID melanoma model
Claudia Felici1, Paola Cafforio1, Francesco Mannavola1, Stucci Luigia Stefania1, Camillo Porta1, Marco Tucci*1
1Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy
Correspondence: Marco Tucci - marco.tucci@uniba.it
Journal of Translational Medicine 2020; 19(Supp 1): 13.

Background: Innovative therapies have improved the overall survival in melanoma although a high number of patients still experience disease progression or recurrence. The clonal heterogeneity of melanoma cells is a critical issue concurring to drug-resistance development and metastatic spreading that, however, could be efficiently forecasted by CTC measurement. A number of studies attempted to validate a method for capturing viable CTCs in metastatic melanoma and a peculiar phenotype and biological properties have been recently correlated with outcome.

Materials and methods: CTCs were obtained from 15 patients with BRAFV600-mutated metastatic melanoma by DEPArray technology and cultured in vitro. Cells established in vitro were definitely transduced with luciferase. The mutational state was assessed by NGS. The CTC phenotype and molecular profile were investigated by cytometry and qPCR. Stemness was investigated by measuring sphere formation and ALDH activity, while limit dilution discriminated the existence of clonal subpopulations. Viability, proliferation and cell cycle were investigated. The tumorigenic potential of subclones was evaluated by their injection in 8-weeks old NOD/SCID mice. Mice were sacrificed while site of metastasis and tumor burden were evaluated by Lumina-SIII. Metastatic tissues were analysed by immunohistochemistry.

Results: A single cell line was established in vitro from a patient with the highest number (n = 102) of CTCs (CTC-AT). Missense mutations
of BRAF, TP53 and PIK3CA occurred in CTC-AT and primary tissue. An intermediate EMT phenotype was demonstrated as a result of the SNAI1, TWIST1, ZEB1 and ZEB2 or both PDL-1 and CD155 levels (Fig. 1). The expression of CD44, CD90, CD10, CD73 or Oct3/4, Nanog and Sox2 confirmed the presence of stem cells, whereas the ALDH activity and sphere formation suggested the stemness (Fig. 2). Three clonal subpopulations showing different proliferative rate were obtained (Fig. 3). In vivo studies revealed the ability of two clones to develop the tumor, although they showed different metastatic potential (Fig. 4).

**Conclusions:** Herein we described a new NOD-SCID model of metastatic melanoma induced by CTCs. The heterogeneity of subclones as well as their stemness support the role of CTCs for investigating the variability of melanoma behaviour and offers the opportunity of pharmacogenomic studies to guide future therapeutic strategies in advanced disease.

**Background:** Metastasis is the major cause of death in malignant melanoma. Several factors, including clinical-pathological and tumor biological features may restrain prognosis. Molecular mechanisms regulating melanoma progression and metastasis have been partially discovered, and thus we developed an in vivo model of metastatic melanoma to investigate potential genes implicated in these events.

**Materials and methods:** To evaluate the in vivo metastatic activity of five different melanoma cell lines (LCP, LCM, WM266, SK-Mel28 and A375), we completed intra-cardiac (ic) injection of $1 \times 10^6$ luminous...
cells or PBS as control in three NOD-SCID mice per cell line. After 3 weeks, mice were studied by in vivo bioluminescence imaging (IVIS Lumina LT) to measure the mean radiance (p/sec/cm²/sr), that we arbitrarily considered as a surrogate of the total metastatic tumor burden (t-MTB). Animals were euthanized at the humane endpoints achievement and underwent X-ray evaluation for bone metastasis detection. The Kaplan-Meier curves described the time to sacrifice from ic injection. Mouse necropsy identified metastatic organs that were explanted and processed for both histology and gene expression analysis. Melanoma cell lines were profiled for gene expression (RNAseq) of 118 genes notably involved in cancer progression and metastasis. Quantitative RT-PCR (qRT-PCR) explored the expression of a restrict number of genes on formalin-fixed paraffin-embedded (FFPE) metastatic samples from euthanized animals.

**Results:** All melanoma cell lines demonstrated a metastatic behaviour following ic injection (Fig. 1) with a variable attitude to produce bone and visceral metastasis (Table 1). Mice injected with LCP, LCM and WM266 showed a lower t-MTB and increased survival (Fig. 2) as compared to A375 and SK-Mel28. Thus, we arbitrarily defined LCP, LCM and WM-266 cell lines ‘poorly metastatic’ (group A), while A375 and SK-Mel28 ‘highly metastatic’ (group B).

The principal component analysis and the unsupervised hierarchical clustering (118 gene transcriptome heatmap) revealed similar gene expression profiling among cell lines grouped for the metastatic attitude (Fig. 3). The gene expression analysis (Fig. 4) performed on FFPE samples identified five deregulated genes (WNT5A, COL6A3, PTHLH, SOX9 and SERPIN1) between A and B.

**Conclusions:** We describe the metastatic capacity of five melanoma cell lines. Gene expression profiling revealed the activation of five genes as putatively responsible for the high aggressiveness of A375 and SK-Mel28 cells. These results suggest to investigate these genes in a clinical setting and their possible application as druggable target for future therapeutic strategies.

**Table 1** (Abstract 14) In vivo organotropism of different melanoma cell lines following intracardiac injection in NOD-SCID mice by x-ray and histology data

|        | Bone | Muscle | Bowel | Adrenal | Lung |
|--------|------|--------|-------|---------|------|
| LCP    | + +  | + +    | +     | + +     | + +  |
| LCM    | + +  | + +    | +     | + +     | + +  |
| WM166  | +    | + +    | +     | +       | + +  |
| A375   | + +  | + +    | +     | +       | +    |
| SK-Mel28 | + + | + +    | +     | +       | +    |

[^+]: number of mice showing specific organ colonization. [1]: micrometastasis

**15. Development of leukoderma as an indicator of clinical response to immune checkpoint inhibitors in melanoma patients**

Sofia Verkhovskaya*, Francesca Romana Di Pietro, Simona Mastroeni, Maria Lucia Carbone, Damiano Abeni, Roberto Morese, Francesca Maria Morelli, Gian Carlo Antonini Cappellini, Stefania D’Atri, Paolo Marchetti, Federica De Galitis, Cristina Maria Failla and Cristina Fortes.

1. Department of Oncology and Dermatological Oncology, ICI-IRCCS, Rome, Italy; 2. Laboratory of Experimental Immunology, ICI-IRCCS, Rome, Italy; 3. Laboratory of Molecular Oncology, ICI-IRCCS, Rome, Italy; 4. Department of Clinical and Molecular Medicine, Oncology Unit, Sant’Andrea Hospital, Sapienza University, Rome, Italy; 5. Medical Oncology Unit B, Policlinico Umberto I, Sapienza University, Rome, Italy.

**Correspondence:** Sofia Verkhovskaya - sofia@pvct.com

**Journal of Translational Medicine 2020, 19(Supp 1): 15.**

**Background:** Although the development of immune checkpoint inhibitors (ICI) has revolutionized the treatment of metastatic melanoma in the last years, more than half of treated patients experience disease progression during therapy. Leukoderma is described as a skin depigmentation like the autoimmune cutaneous disease vitiligo. Cases of spontaneous leukoderma have been reported in melanoma patients and are associated with a favorable outcome [1]. Moreover, leukoderma sometime appears in melanoma patients subjected to immunotherapies such as interleukin 2, tumor vaccines or ICI [1, 2]. However, no consensus has been reached regarding the development of leukoderma and improved overall survival. The aim of our study was to evaluate a possible association between the appearance of leukoderma during ICI treatment and a better prognosis.

**Materials and methods:** We identified 280 patients followed at the IDI-IRCCS in the last 10 years who had inoperable or metastatic melanoma and had undergone ICI therapy in any line of treatment. Primary endpoint was to evaluate the association between leukoderma appearance and the risk of mortality. Secondary endpoints were to evaluate the association between leukoderma appearance and the response to treatment or time to the next treatment (TTNT), defined as the time between the start of treatment with ICI and the decision to change the treatment because of no clinical benefit or toxicity.

**Results:** In the multivariate Cox model, a protective effect for mortality was found for the onset of leukoderma (HR = 0.23; 95% CI = 0.11–0.44, p < 0.0001), while high lactate dehydrogenases levels above upper limits of normal (HR = 2.33; 95% CI = 1.51–3.60, p < 0.0001) and stage M1d (M1d versus Mla-M1b) (HR = 2.25; 95% CI = 1.39–3.63, p = 0.001) were associated with an increased risk of mortality. In a sub-group analysis (only cutaneous melanoma in first line treatment, N = 153), occurrence of leukoderma was also an independent predictor factor for duration of clinical benefits measured by TTNT.

**Conclusions:** In conclusion, our findings suggest that leukoderma development could be considered as a biomarker of successful response to ICI treatment.

**Ethics Approval:** For this study, approval was obtained from the Ethics Committee of the IDI-IRCCS (Opinion Register No. 510 and subsequent amendments).

**References**

1. Failla CM, Carbone ML, Fortes C, Pagnanelli G, D’Atri S. Melanoma and Vitiligo: In Good Company. Int J Mol Sci. 2019; 20:5731.
2. Cortellini A, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin Oncol. 2019; 46(3):362–371.

**16. Response for combination of PV-10 autolytic immunotherapy and immune checkpoint blockade in checkpoint-refractory patients**

Jonathan S Zager 1, Amod A Sarnaik 1, Shari Pilon-Thomas 1, Matthew Beatty 1, Dale Han 3, Gary Lu 3, Sanjiv S Agarwala 4, Merrick I Ross 5, Keisuki Shirai 5, Richard Essner 7, Bernard M Smithers 8, Victoria Atkinson 5, Dominic Rodrigues 5, and Eric A Wachter 9.*

1. Moffitt Cancer Center, Tampa, FL USA; 2. Oregon Health & Science University, Portland, OR USA; 3. St. Luke’s University Health Network, Bethlehem, PA USA; 4. Temple University, Philadelphia, PA USA; 5. MD Anderson Cancer Center, Houston, TX USA; 6. Dartmouth-Hitchcock Medical Center, Lebanon, NH USA; 7. John Wayne Cancer Institute, Santa Monica, CA USA; 8. Princess Alexandra Hospital, Brisbane, QLD, AUS; 9. Provectus Biopharmaceuticals, Inc., Knoxville, TN USA.

**Correspondence:** Eric A. Wachter - wachter@pvct.com

**Journal of Translational Medicine 2020, 19(Supp 1): 16.**
Background: PV-10, an injectable formulation of rose bengal disodium, is a small molecule autolytic immunotherapy in development for solid tumors; intralesional injection can yield immunogenic cell death and tumor-specific reactivity in circulating T cells [1–4]. PV-10 is currently the subject of a Phase 1b/2 study in combination with immune checkpoint blockade (CB) in patients with advanced cutaneous melanoma (NCT02557321).

Materials and methods: Participants must have at least 1 injectable lesion, at least 1 measurable target lesion (TL), and be candidates for pembrolizumab. Patients receive combination treatment q3w for 5 cycles followed by pembrolizumab alone q3w (total duration of up to 24 months); the primary endpoint is safety and tolerability, with objective response rate (ORR) and progression-free survival (PFS) as key secondary endpoints assessed via RECIST 1.1 after 15 weeks, then q12w. Immune correlative assessments are being performed on a subgroup of patients.

Results: An expansion cohort is accruing up to 24 CB-refractory patients; early results of the first 15 patients (2 Stage M0, 4 M1a, 2 M1b, 5 M1c, 2 M1d) are presented here; all had one or more prior lines of CB (9 were refractory to CTLA-4 and PD-1). Treatment-Emergent Adverse Events were consistent with established patterns, principally Grade 1–2 injection site reactions attributed to PV-10 and Grade 1–3 immune-mediated reactions attributed to pembrolizumab, with no unexpected overlapping toxicities. This profile is similar to CB-naïve patients in the main cohort of the study. [5]. As of the data cutoff, 12 patients were evaluable for overall response by RECIST: 33% ORR, 1 CR (M1a) and 3 PRs (2 M0 and M1d); 3 patients (M1a, M1b, and M1c) achieved SD for a disease control rate (DCR) of 58%. These patients had 31 TLs; 17 were injected with PV-10 and achieved 29% CR, 41% ORR, and 59% DCR on a per lesion basis. These patterns parallel those observed in CI-naïve patients [5]. Five patients completed correlative assessment: 2 exhibited increased High Mobility Group Box 1 (HMG1B1), a DAMP molecule associated with the activation of dendritic cells; and 1 patient refractory to combination CTLA-4/PD-1 exhibited increased T cell reactivity to HLA-matched tumor that preceded a durable CR. Similar immune upregulation has been shown with single-agent PV-10 in CB-naïve patients [4].

Conclusion: Encouraging response, both at patient- and injected lesion-levels, coupled with a non-overlapping safety profile, support ongoing enrollment. Pharmacodynamic assessments substantiate PV-10’s immune-mediated mechanism in CB-refractory patients.

References
1. Wachter E, Dees C, Harkins J, Fisher W, Scott T. Functional imaging of photodynamic sensitizers using multiphoton microscopy. Proceedings of SPIE, Multiphoton Microscopy in the Biomedical Sciences II, Penasamy, A. and So, P.T.C. (eds), Bellingham, Washington; 2002; 4620:143–147.
2. Liu H, Innamarato PP, Kodumudi K, Weber A et al. Intralesional rose bengal in melanoma elicits immune-mediated mechanism in CD8+ T cells via activation of dendritic cells by the release of high mobility group box 1. Oncotarget 2016; 7:37893–37905.
3. Qin J, Kunda N, Qiao G, Calata JF et al. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death and Disease 2017; 8:e2584, Doi: https://doi.org/10.1038/cdd.2016.477.
4. Liu H, Weber A, Morse J, Kodumudi K, Weber A et al. Intralesional rose bengal in melanoma elicits immune-mediated mechanism in CD8+ T cells via activation of dendritic cells by the release of high mobility group box 1. Oncotarget 2016; 7:37893–37905.
5. Agawala S, Ross M, Zager J, Samsaik A et al., A phase 1b study of rose bengal disodium and anti-PD-1 in metastatic melanoma: results in patients naive to immune checkpoint blockade. ESMO Virtual Congress 2020, presentation 1125P.

17. The impact of brain involvement in metastatic melanoma patients treated with pembrolizumab
Michael Weichenthal1,*, Scherrer Emiline2, Sheenu Chandwani3, Peter Mohr2, Ullrike Leite2, Selma Ugurel4, Katharina C. Kahler5, Ralf Gutzmee6, Claudia Pfuhler7, Jessica Hassel8, Dirk Debus2, Jens Ulrich2, Evelyn Dabrowski2, Thomas Eigentler6, Rudolf Herbst9, Julia Welzel2, Carmen Loquai10, Friedegund Meier11, Dirk Schadenordt12
1Department of Dermatology, University of Kiel, Kiel, Germany; 2The ADOReg Study Group, Berlin, Germany; 3 Merck & Co., Inc., Kenilworth, NJ, USA; 4Elbe-Kliniken Buxtehude, Buxtehude, Germany; 5 Skin Cancer Center, Buxtehude, Germany; 6 Skin Cancer Center, Tübingen, Germany; 7 University of Essen, Essen, Germany; 8 Skin Cancer Center, Kiel, Germany; 9 Skin Cancer Center, Hannover, Germany; 10 Saarland University Hospital, Homburg, Germany; 11 University of Heidelberg, Heidelberg, Germany; 12 Skin Cancer Center, Lübeck, Germany; 13 Department of Dermatology, Gera, Germany; 14 University Department of Dermatology, Mannheim, Germany; 15 University Department of Dermatology, Regensburg, Germany; 16 University Department of Dermatology, Ulm, Germany; 17 University Department of Dermatology, Heidelberg, Germany; 18 Skin Cancer Center, Dortmund, Germany; 19 Skin Cancer Center, Bremen, Germany; 20 University Department of Dermatology, Munich, Germany; 21 Skin Cancer Center, Nuremberg, Germany; 22 Skin Cancer Center, Quedlinburg, Germany; 23 Skin Cancer Center, Ludwigshafen, Germany; 24 Skin Cancer Center, Erfurt, Germany; 25 University of Augsburg, Augsburg, Germany; 26 Skin Cancer Center, Mainz, Germany; 27 University Department of Dermatology, Dresden, Germany

Correspondence: Michael Weichenthal - mweichenthal@dermatology.uni-kiel.de
Journal of Translational Medicine 2020, 19(Suppl 1): 17.

Background: The anti-PD1 antibody pembrolizumab is established as a standard of care in European patients with metastatic melanoma (MM). Melanoma brain metastases (MBM) are a common and serious tumour manifestation in MM. We examined pembrolizumab use and associated outcomes in patients with MBM.

Materials and methods: Real-world data from the German ADOReg skin cancer registry was used to evaluate 664 adult patients with advanced stage IV or non-resectable stage III melanoma on pembrolizumab treatment with follow-up through December 31, 2019. Overall survival (OS) and real-world time on treatment (rwToT) from pembrolizumab initiation were analysed for patients with and without known baseline MBM using the Kaplan-Meier (KM) method. Multivariable Cox regression was used to control for potential confounding factors including performance status (ECOG), line of treatment, serum lactate dehydrogenase (LDH), and number of metastatic sites. For patients with MBM, the number of brain lesions and the role of concurrent radiotherapy were analysed.

Results: Pembrolizumab was administered to 401 (60%), 143 (22%), and 129 (18%) patients as first, second-, or higher line of treatment, respectively. Overall, 39% had elevated LDH, and 27% had ECOG > 1. Most patients (66.4%) had two or more metastatic sites, and 164 (24.7%) patients had brain metastases at pembrolizumab initiation. Survival at 24 months was similar between patients with a single brain lesion (58.7%) and those without brain involvement (59%), but lower for patients with multiple MBM (40.0%), (Table 1). Patients without known baseline MBM had a median OS of 32.8 (95% CI 27.6–39.8) months, while those with a single or multiple brain lesions had median OS of 47.2 (95% CI 16.00-NR) months and 19.6 (95%CI 13.7–30.3) months, respectively (p<0.01).

KM median rwToT was similar for patients with (6.0 months) or without MBM (6.3 months). (Table 1) The observed difference between patients with one brain lesion (6.5 months) and those with multiple MBM (5.1 months) was not significant (p=0.23).

Radiotherapy to the brain was delivered upfront or concurrently with pembrolizumab in similar rates for patients with single brain lesions (32.6%) and multiple lesions (34.9%). Concurrent radiotherapy did not significantly affect OS or rwToT in patients with MBM in multivariable Cox analysis.

Conclusion: These findings support effectiveness of pembrolizumab in real-world clinical settings and in patients with MBM. Patients with a single brain lesion and those without MBM seem to benefit equally from pembrolizumab treatment. Previously published findings suggesting a synergistic effect of concurrent brain radiotherapy could not be confirmed.
Table 1  (Abstract 17) Summary of real-world outcomes of patients with melanoma brain metastasis in the German ADOReg skin cancer registry

|                                | No melanoma brain metastases N = 500 | Any melanoma brain metastases | At least one melanoma brain metastasis N = 164 | Single melanoma brain metastasis N = 46 | Two or more melanoma brain metastases N = 106 |
|--------------------------------|--------------------------------------|------------------------------|-----------------------------------------------|----------------------------------------|-----------------------------------------------|
| Survival rate at 24 months, %  | 58.9%                                | 45.7%                        | 58.7%                                         | 40.0%                                  |
| Median OS in months (95% CI)   | 32.8 (27.6–39.8)                     | 19.6 (13.7–30.3)             | 47.2 (16.0–NR)                               | 16.7 (10.4–25.1)                      |
| Median rwToT in months (95% CI) | 6.3 (5.3–7.2)                        | 6.0 (4.1–6.9)                | 6.5 (3.1–12.5)                               | 5.1 (3–5.7)                            |

*12 patients had brain metastasis information at baseline, but the number of lesions was unknown; these patients were excluded from analysis by number of brain lesions.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.